These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 33176727)

  • 1. Treating male partners of women with bacterial vaginosis (StepUp): a protocol for a randomised controlled trial to assess the clinical effectiveness of male partner treatment for reducing the risk of BV recurrence.
    Vodstrcil LA; Plummer EL; Doyle M; Fairley CK; McGuiness C; Bateson D; Hocking JS; Law MG; Petoumenos K; Donovan B; Chow EPF; Bradshaw CS;
    BMC Infect Dis; 2020 Nov; 20(1):834. PubMed ID: 33176727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Prospective, Open-Label Pilot Study of Concurrent Male Partner Treatment for Bacterial Vaginosis.
    Plummer EL; Vodstrcil LA; Doyle M; Danielewski JA; Murray GL; Fehler G; Fairley CK; Bulach DM; Garland SM; Chow EPF; Hocking JS; Bradshaw CS
    mBio; 2021 Oct; 12(5):e0232321. PubMed ID: 34663095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined oral and topical antimicrobial therapy for male partners of women with bacterial vaginosis: Acceptability, tolerability and impact on the genital microbiota of couples - A pilot study.
    Plummer EL; Vodstrcil LA; Danielewski JA; Murray GL; Fairley CK; Garland SM; Hocking JS; Tabrizi SN; Bradshaw CS
    PLoS One; 2018; 13(1):e0190199. PubMed ID: 29293559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial.
    Bradshaw CS; Pirotta M; De Guingand D; Hocking JS; Morton AN; Garland SM; Fehler G; Morrow A; Walker S; Vodstrcil LA; Fairley CK
    PLoS One; 2012; 7(4):e34540. PubMed ID: 22509319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronidazole versus lactic acid for treating bacterial vaginosis (VITA): protocol for a randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis.
    Armstrong-Buisseret L; Brittain C; David M; Dean G; Griffiths F; Hepburn T; Jackson L; Kai J; Montgomery A; Roberts T; Thandi S; Ross JDC
    Trials; 2019 Nov; 20(1):648. PubMed ID: 31775859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of male partners and recurrence of bacterial vaginosis: a randomised trial.
    Colli E; Landoni M; Parazzini F
    Genitourin Med; 1997 Aug; 73(4):267-70. PubMed ID: 9389947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment considerations for bacterial vaginosis and the risk of recurrence.
    Chen JY; Tian H; Beigi RH
    J Womens Health (Larchmt); 2009 Dec; 18(12):1997-2004. PubMed ID: 20044862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use.
    Bradshaw CS; Vodstrcil LA; Hocking JS; Law M; Pirotta M; Garland SM; De Guingand D; Morton AN; Fairley CK
    Clin Infect Dis; 2013 Mar; 56(6):777-86. PubMed ID: 23243173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptability of and treatment preferences for recurrent bacterial vaginosis-Topical lactic acid gel or oral metronidazole antibiotic: Qualitative findings from the VITA trial.
    Anstey Watkins J; Ross JDC; Thandi S; Brittain C; Kai J; Griffiths F
    PLoS One; 2019; 14(11):e0224964. PubMed ID: 31730666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Male Sexual Partners of Women With Bacterial Vaginosis: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Schwebke JR; Lensing SY; Lee J; Muzny CA; Pontius A; Woznicki N; Aguin T; Sobel JD
    Clin Infect Dis; 2021 Aug; 73(3):e672-e679. PubMed ID: 33383580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: the VITA RCT.
    Armstrong-Buisseret L; Brittain C; Kai J; David M; Anstey Watkins J; Ozolins M; Jackson L; Abdali Z; Hepburn T; Griffiths F; Montgomery A; Daniels J; Manley A; Dean G; Ross JD
    Health Technol Assess; 2022 Jan; 26(2):1-170. PubMed ID: 35057905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection.
    Pendharkar S; Brandsborg E; Hammarström L; Marcotte H; Larsson PG
    BMC Infect Dis; 2015 Jul; 15():255. PubMed ID: 26137971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing the regulatory framework in South Africa - a single-blind randomized pilot trial of commercial probiotic supplementation to standard therapy in women with bacterial vaginosis.
    Happel AU; Singh R; Mitchev N; Mlisana K; Jaspan HB; Barnabas SL; Passmore JS
    BMC Infect Dis; 2020 Jul; 20(1):491. PubMed ID: 32650729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and Treatment of Recurrent Bacterial Vaginosis.
    Faught BM; Reyes S
    J Womens Health (Larchmt); 2019 Sep; 28(9):1218-1226. PubMed ID: 31403349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The DEVA trial: protocol for a randomised controlled trial of dequalinium chloride versus usual care antibiotics for the treatment of bacterial vaginosis.
    Haydock R; Hepburn T; Ross J; Daniels J; Brittain C; Jackson L; Ozolins M; Wilson J
    Trials; 2022 Dec; 23(1):1040. PubMed ID: 36544202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
    Bradshaw CS; Morton AN; Hocking J; Garland SM; Morris MB; Moss LM; Horvath LB; Kuzevska I; Fairley CK
    J Infect Dis; 2006 Jun; 193(11):1478-86. PubMed ID: 16652274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic treatment for the sexual partners of women with bacterial vaginosis.
    Amaya-Guio J; Viveros-Carreño DA; Sierra-Barrios EM; Martinez-Velasquez MY; Grillo-Ardila CF
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD011701. PubMed ID: 27696372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BASIC study: is intravaginal boric acid non-inferior to metronidazole in symptomatic bacterial vaginosis? Study protocol for a randomized controlled trial.
    Zeron Mullins M; Trouton KM
    Trials; 2015 Jul; 16():315. PubMed ID: 26210791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial.
    Paavonen J; Mangioni C; Martin MA; Wajszczuk CP
    Obstet Gynecol; 2000 Aug; 96(2):256-60. PubMed ID: 10908773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacteriological epidemiology and treatment of bacterial vaginosis.
    Mikamo H; Kawazoe K; Izumi K; Ito K; Katoh N; Watanabe K; Ueno K; Tamaya T
    Chemotherapy; 1996; 42(1):78-84. PubMed ID: 8751270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.